May 2006
Volume 47, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2006
Vigamox® (0.5% Moxifloxacin) Is Effective in Reducing Staphylococcus aureus Colony Counts in a NZW Rabbit Endophthalmitis Model
E.G. Romanowski; R.P. Kowalski; K.A. Yates; F.S. Mah; Y.J. Gordon
Author Affiliations & Notes
  • E.G. Romanowski
    The Charles T. Campbell Laboratory, UPMC Eye Center, Ophthalmology and Visual Sciences Research Center, Eye and Ear Institute, Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, PA
  • R.P. Kowalski
    The Charles T. Campbell Laboratory, UPMC Eye Center, Ophthalmology and Visual Sciences Research Center, Eye and Ear Institute, Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, PA
  • K.A. Yates
    The Charles T. Campbell Laboratory, UPMC Eye Center, Ophthalmology and Visual Sciences Research Center, Eye and Ear Institute, Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, PA
  • F.S. Mah
    The Charles T. Campbell Laboratory, UPMC Eye Center, Ophthalmology and Visual Sciences Research Center, Eye and Ear Institute, Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, PA
  • Y.J. Gordon
    The Charles T. Campbell Laboratory, UPMC Eye Center, Ophthalmology and Visual Sciences Research Center, Eye and Ear Institute, Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, PA
  • Footnotes
    Commercial Relationships  E.G. Romanowski, Alcon Laboratories, F; Alcon Laboratories, Allergan Inc., C; R.P. Kowalski, Alcon Laboratories, F; Alcon Laboratories, Allergan Inc., C; K.A. Yates, Alcon Laboratories, F; F.S. Mah, Alcon Laboratories, F; Alcon Laboratories, Allergan Inc., C; Y.J. Gordon, Alcon Laboratories, F; Alcon Laboratories, Allergan Inc., C.
  • Footnotes
    Support  Alcon Laboratories, NIH Grants EY08227 and EY08098, Eye & Ear Foundation, and RPB
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 1899. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      Vigamox® (0.5% Moxifloxacin) Is Effective in Reducing Staphylococcus aureus Colony Counts in a NZW Rabbit Endophthalmitis Model
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      E.G. Romanowski, R.P. Kowalski, K.A. Yates, F.S. Mah, Y.J. Gordon; Vigamox® (0.5% Moxifloxacin) Is Effective in Reducing Staphylococcus aureus Colony Counts in a NZW Rabbit Endophthalmitis Model . Invest. Ophthalmol. Vis. Sci. 2006;47(13):1899.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Purpose: : The goal of the current study was to determine whether the commercially available and self–preserved Vigamox® (0.5% moxifloxacin ophthalmic solution, Alcon Laboratories, Ft. Worth, TX) could be used as an effective treatment of an established endophthalmitis in the NZW rabbit endophthalmitis model.

Methods: : The left eyes of 24 NZW rabbits were inoculated into the vitreous with approximately 500 cfu of a clinical endophthalmitis isolate of Staphylococcus aureus. 24 hours post–inoculation, the rabbits were randomly divided into 3 groups of 8 rabbits each. Group I eyes were treated intravitreally with 100 µl of Vigamox® (500 µg of moxifloxacin). Group II eyes were treated intravitreally with 100 µl of 10 mg/ml vancomycin (1 mg of vancomycin). Group III eyes received no treatment (Control). 24 hours post–treatment and 48 hours post–inoculation, the rabbits were euthanized and samples of vitreous were removed from the test eyes for standard colony count evaluation. Colony counts were Log10 transformed and analyzed using ANOVA.

Results: : Both the Vigamox® (1.6 ± 1.6 Log10 cfu/ml) and vancomycin (0.1 ± 0.3 Log10 cfu/ml) treated eyes demonstrated significantly fewer S. aureus colony counts compared to the untreated Control (4.7 ± 2.0 Log10 cfu/ml) (p=0.000, power = 0.9996). There was no significant difference in colony counts between the Vigamox® and vancomycin treated eyes.

Conclusions: : Intravitreal Vigamox® was as effective as vancomycin in the NZW rabbit endophthalmitis model using microbiological outcome parameters. Based on the results of this study, Vigamox® may have the potential be an effective adjunctive treatment for S. aureus endophthalmitis. However, clinical trials are necessary to determine the safety and efficacy of Vigamox® treatment of endophthalmitis in patients.

Keywords: endophthalmitis • antibiotics/antifungals/antiparasitics • Staphylococcus 
© 2006, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Permission to republish any abstract or part of an abstract in any form must be obtained in writing from the ARVO Office prior to publication.
Copyright © 2025 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept